Abivax shares jump 36% as new trial data support ulcerative colitis drug obefazimod

Read full story on Euronews
Share
Abivax shares jump 36% as new trial data support ulcerative colitis drug obefazimod
AI disclosure

Summary

French biotech company Abivax said new clinical trial data supports the safety and effectiveness of its experimental ulcerative colitis treatment.

Original reporting

Open original source

Related coverage

Read full article on Euronews

Get the AFBytes Brief

Major stories, AI-assisted analysis, and what to watch next. Free, monthly, unsubscribe anytime.